Short bowel syndrome affect the functional capability of intestine. Patients suffering from short bowel syndrome have a reduced ability to absorb trace elements, fats, vitamins, fluids, minerals and carbohydrates and can experience weight loss, malnutrition, diarrhea and dehydration. Presently, there is no cure for short bowel syndrome and the treatment is targeted towards symptoms. In a few cases, short bowel syndrome can be life-threatening but usually, the disease can managed through effective medication.
In most cases, short bowel syndrome is associated with small intestine surgeries. It is typically acquired over the individual’s lifespan and in only a few cases, it is a genetic occurrence. Treatment mainly includes nutrition & diet management, medication and surgery.
In medication, teduglutide was first approved by the FDA for short bowel syndrome disorder. Other treatments include antidiarrheal, histamine blockers, proton pump inhibitors and growth hormones.
Access Full TOC of This Report @ https://www.persistencemarketresearch.com/toc/24094
Short Bowel Syndrome Treatment Market: Drivers and Restraints
Rising awareness and availability of epidemiological data lead to the better management of short bowel disease. Further, rapid improvements in the field of healthcare have increased awareness regarding short bowel syndrome and thus, created opportunities. Along with these, non-profit organizations are promoting research & development around short bowel syndrome in joint scientific research between the public sector and the private sector.
In association with non-profit organizations, state governments provide special incentives to manufacturers for the development of short bowel syndrome drugs. The development of short bowel syndrome drugs is at a nascent stage, which creates more opportunities for global players. Public-private partnerships are encouraging pharmaceutical companies to develop new orphan drugs for short bowel syndrome.
A few countries have implemented a combination of legislations, regulations, and policies promoting drug development for short bowel syndrome. All these factors act as potential drivers for the growth of the short bowel syndrome market.
On the other hand, a lack of approved treatment options may lead to the slow growth of the short bowel syndrome market. Apart from this, awareness among physicians is still a problem in a few parts of the globe.
To Remain ‘Ahead’ Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/24094
Short Bowel Syndrome Treatment Market: Segmentation
Segmentation on the basis of drug type,
- Glucagon-like Peptide
- Histamine Blockers
- Proton Pump Inhibitors
- Growth Hormone
Segmentation on the basis of distribution channel,
- Hospital Pharmacies
- Specialty Pharmacies
Short Bowel Syndrome Treatment Market: Market Overview
The global short bowel syndrome treatment market has witnessed robust growth due to the increasing demand for drugs. The short bowel syndrome market is marked by the presence of limited manufacturers for approved therapies, which is paving way for huge opportunities in terms of market acquisitions and price flexibility. In case of symptomatic treatment, stiff competition exists among major players and there is limited scope for small companies/domestic players.
Attributing to this, government bodies are directly taking part in encouraging local manufacturers through various initiatives. Apart from this, non-profit organizations are taking part in healthcare advocacy and public awareness. Primary advocacy focuses on improvement of the healthcare system, i.e. diagnosis, treatment and support with comparatively less emphasis on research and drug development.
Short Bowel Syndrome Treatment Market: Region-Wise Overview
The global short bowel syndrome treatment market can be segmented into the following regions – North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and the Middle East & Africa.
North America dominates the global short bowel syndrome treatment market, mainly due to the strong healthcare system and reimbursement policies in the region. North America, particularly the U.S., is a dominant region in the market, due to high adoption among end users.
Europe and the Asia Pacific are pegged to be the fastest growing regions, due to growing awareness regarding short bowel syndrome among physicians and patients. Lack of awareness and healthcare facilities in Latin America and MEA will contribute to the regions’ to poor growth.
Short Bowel Syndrome Treatment Market: Market Participants
Key participants operating in the short bowel syndrome treatment market include Shire Plc, Merck & Company, Inc., Swedish Orphan Biovitrum AB, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., AstraZeneca Plc, Johnson & Johnson and others. Players mainly focus on collaborations and partnerships to keep pace with the competition and develop new products.
For In-Depth Competitive Analysis, Buy Now @ https://www.persistencemarketresearch.com/checkout/24094
The report covers an exhaustive analysis on,
- Market Segments
- Market Dynamics
- Historical Actual Market Size, 2013 – 2017
- Market Size & Forecast, 2018 to 2026
- Supply & Demand Value Chain
- Market Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
- Aircraft Refurbishing Market Drivers and Restraints
Regional analysis for market includes,
- North America
- Latin America
- Asia Pacific & Japan
- Middle East & Africa
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current and projected industry size, recent industry trends
- Key Competition landscape
- Strategies for key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
More About the Report –
Unprecedented access to a world of information has given rise to the empowered, albeit distrustful, consumer. So is the case with healthcare, where the patient has been rendered more informed and conscientious thanks to the extraordinary penetration of the Internet. The discerning patient now demands more affordable, sophisticated, transparent, and personalized healthcare services, creating the need for new models for care.
The advent of health information technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor-neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.
Explore Extensive Coverage of PMR`s Life Sciences & Transformational Health Landscape
Molecular Diagnostics Market –
Molecular Diagnostics Market Segmentation by Key Players – Novartis AG, Roche Diagnostics, QIAGEN, Siemens Healthcare, Abbott Laboratories, Inc., Gen-Probe, Inc. (Hologic Inc.), Cepheid, Inc., Beckman Coulter, Inc., Becton, Dickinson & Company, Myriad Genetics, Inc., and bioMerieux.
Next-Generation Sequencing Market –
Next Generation Sequencing Market Segmented by(By Application – Whole-genome Sequencing ,Exome Sequencing,Targeted Resequencing,De Novo Sequencing,RNA Sequencing,ChIP Sequencing,Methyl Sequencing,Others);By Technology- Targeted Sequencing & Resequencing,Whole Genome Sequencing,Whole Exome Sequencing.
Ophthalmology devises Market –
Ophthalmology devises Market Segmentation by Key Players – Abbott Medical Optics Inc., Carl Zeiss Meditec AG, Bausch & Lomb Inc., Essilor International S.A, Ziemer Ophthalmic Systems AG and Topcon Corporation.
Intravenous Iron Drugs Market –
Intravenous (IV) Iron Drugs Market Segmentation by Key Players- Actavis, Inc., AMAG Pharmaceuticals, Inc., Galenica Ltd., Fresenius Medical Care AG & Co. KGaA, Vifor Pharma Ltd., American Regent, Inc., Luitpold Pharmaceuticals, Inc., Pharmacosmos A/S, Rockwell Medical Technologies, Inc., and Sanofi.
Syndromes Progressive Ataxia Weakness Disorders Market –
Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Market Segmentation by Key Players- Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMR’s collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.